JMDSJournal of Medicines Development Sciences2382-63632382-6371Bio-Byword Scientific Publishing Pty. Ltd.10.26689/JMDS.v11i3.16018ArticleExploring the Potential Mechanisms of Compound Banmao Capsule Against Ovarian Cancer Through Network Pharmacology and Bioinformaticshttps://artdesignp.com/journal/JMDS/11/3/10.26689/JMDS.v11i3.16018LiuXu,LiuAikun20261132026-09-16The objective of this study was to characterize the potential mechanisms underlying the suppressive effects of Compound Banmao Capsule (CBC) on ovarian cancer (OC) using network pharmacology combined with bioinformatics. CBC-associated targets and OC-related targets were retrieved from public databases, and overlapping targets were identified and analyzed using a PPI network. GO and KEGG enrichment analyses were performed to identify relevant biological functions and signal pathways. Gene expression and clinical associations were further investigated using the GEPIA database. Fourteen overlapping targets were identified: AKR1B1, GJA1, BCL2, ESR1, CCL2, COL3A1, MMP1, DPP4, TNF, IL1B, F3, PTGS2, IL6, and VCAM1. GO enrichment analysis indicated that these targets were associated with multiple biological processes, particularly inflammatory responses, immune regulation, and the regulation of nitric oxide biosynthesis and interleukin-8 production. KEGG enrichment analysis highlighted several cancer-related and immune-associated pathways, including the AGE-RAGE, IL-17, TNF, NF-κB, NOD-like receptor, and C-type lectin receptor signaling pathways. GEPIA analysis further revealed differences in the expression of several candidate targets between OC and normal ovarian tissues and associations between selected genes and clinical characteristics. Taken together, this study provides a systematic overview of the potential targets and signaling pathways associated with CBC in OC, offering bioinformatics-based insights for further investigation of its underlying mechanisms.Compound Banmao capsule, Ovarian cancer, Network pharmacology, Bioinformatics

[1] Wu M, Zhou S, 2023, Harnessing Tumor Immunogenomics: Tumor Neoantigens in Ovarian Cancer and Beyond. Biochim Biophys Acta Rev Cancer, 1878(6): 189017. [2] Sun C, Li X, Teng Q, et al., 2025, Targeting Platinum-Resistant Ovarian Cancer by Disrupting Histone and RAD51 Lactylation. Theranostics, 15(7): 3055–3075. [3] Tossetta G, Inversetti A, 2024, Special Issue "Ovarian Cancer: Advances on Pathophysiology and Therapies". Int J Mol Sci, 25(10): 5282. [4] Kordowitzki P, Lange B, Elias KM, et al., 2025, Transforming Treatment Paradigms: Focus on Personalized Medicine for High-Grade Serous Ovarian Cancer. CA Cancer J Clin, 75(5): 436–460. [5] Wang Y, Xie L, Liu F, et al., 2024, Research Progress on Traditional Chinese Medicine-Induced Apoptosis Signaling Pathways in Ovarian Cancer Cells. J Ethnopharmacol, 319(Pt 2): 117299. [6] Zhang X, Wei X, Shi L, et al., 2025, The Latest Research Progress: Active Components of Traditional Chinese Medicine as Promising Candidates for Ovarian Cancer Therapy. J Ethnopharmacol, 337(Pt 1): 118811. [7] Li S, Chen X, Shi H, et al., 2025, Tailoring Traditional Chinese Medicine in Cancer Therapy. Mol Cancer, 24(1): 27. [8] Li L, Zhu L, Zhu J, et al., 2017, Mechanisms of Inhibiting Human Leukemia Cell Lines by Serum of Rats Treated with Compound Banmao Capsule. Oncol Lett, 14(4): 4092–4098. [9] Hu Y, Xiao Y, Wan L, et al., 2024, Network Pharmacology to Reveal the Mechanism of Fufang Banmao Capsule for Treating Unresectable Primary Liver Cancer and Clinical Data Validation. Curr Pharm Des, 30(35): 2785–2796. [10] Li K, Xiao K, Zhu S, et al., 2022, Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges. Front Pharmacol, 13: 889799. [11] Zhang P, Zhang D, Zhou W, et al., 2023, Network Pharmacology: Towards the Artificial Intelligence-Based Precision Traditional Chinese Medicine. Brief Bioinform, 25(1): bbad518. [12] Nogales C, Mamdouh ZM, List M, et al., 2022, Network Pharmacology: Curing Causal Mechanisms Instead of Treating Symptoms. Trends Pharmacol Sci, 43(2): 136–150. [13] Zhao L, Zhang H, Li N, et al., 2023, Network Pharmacology, a Promising Approach to Reveal the Pharmacology Mechanism of Chinese Medicine Formula. J Ethnopharmacol, 309: 116306. [14] Li Y, Hu Y, Yang L, et al., 2023, Luteolin Directly Binds to KDM4C and Attenuates Ovarian Cancer Stemness via Epigenetic Suppression of PPP2CA/YAP Axis. Biomed Pharmacother, 160: 114350. [15] Luo H, Rankin GO, Liu L, et al., 2009, Kaempferol Inhibits Angiogenesis and VEGF Expression Through Both HIF-Dependent and Independent Pathways in Human Ovarian Cancer Cells. Nutr Cancer, 61(4): 554–563. [16] Luo H, Jiang B, Li B, et al., 2012, Kaempferol Nanoparticles Achieve Strong and Selective Inhibition of Ovarian Cancer Cell Viability. Int J Nanomedicine, 7: 3951–3959. [17] Yang SY, Jhang JS, Huang WL, et al., 2025, Wogonin Inhibits Ovarian Cancer by Activating the AMPK-TET2-5hmC Axis. Mol Carcinog, 64(3): 440–449. [18] Xing F, Sun C, Luo N, et al., 2019, Wogonin Increases Cisplatin Sensitivity in Ovarian Cancer Cells Through Inhibition of the Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway. Med Sci Monit, 25: 6007–6014.